share_log

Private Companies Among Bio-Thera Solutions, Ltd.'s (SHSE:688177) Largest Stockholders and Were Hit After Last Week's 12% Price Drop

Private Companies Among Bio-Thera Solutions, Ltd.'s (SHSE:688177) Largest Stockholders and Were Hit After Last Week's 12% Price Drop

Bio-Thera Solutions, Ltd. 中的私營公司s(SHSE: 688177)最大的股東,在上週股價下跌12%後受到打擊
Simply Wall St ·  04/19 07:59

Key Insights

關鍵見解

  • The considerable ownership by private companies in Bio-Thera Solutions indicates that they collectively have a greater say in management and business strategy
  • A total of 4 investors have a majority stake in the company with 54% ownership
  • Institutional ownership in Bio-Thera Solutions is 11%
  • 私營公司在Bio-Thera Solutions中的大量所有權表明,它們在管理和業務戰略中集體擁有更大的發言權
  • 共有4位投資者持有該公司的多數股權,所有權爲54%
  • Bio-Thera Solutions的機構所有權爲11%

If you want to know who really controls Bio-Thera Solutions, Ltd. (SHSE:688177), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are private companies with 51% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

如果你想知道誰真正控制了Bio-Thera Solutions, Ltd.(SHSE: 688177),那麼你必須看看其股票登記處的構成。而持有最大份額的集團是擁有51%所有權的私營公司。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

And last week, private companies endured the biggest losses as the stock fell by 12%.

上週,私營公司遭受了最大的損失,股價下跌了12%。

Let's delve deeper into each type of owner of Bio-Thera Solutions, beginning with the chart below.

讓我們從下圖開始,深入研究Bio-Thera Solutions的每種類型的所有者。

ownership-breakdown
SHSE:688177 Ownership Breakdown April 18th 2024
SHSE: 688177 所有權明細 2024 年 4 月 18 日

What Does The Institutional Ownership Tell Us About Bio-Thera Solutions?

關於Bio-Thera解決方案,機構所有權告訴我們什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見指數的回報進行比較。因此,他們通常會考慮收購相關基準指數中包含的大型公司。

Bio-Thera Solutions already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Bio-Thera Solutions' historic earnings and revenue below, but keep in mind there's always more to the story.

Bio-Thera Solutions已經在股票登記處設立了機構。事實上,他們擁有該公司可觀的股份。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。當多家機構擁有一隻股票時,總是存在處於 “擁擠交易” 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到Bio-Thera Solutions的歷史收益和收入,但請記住,故事總是有更多內容。

earnings-and-revenue-growth
SHSE:688177 Earnings and Revenue Growth April 18th 2024
SHSE: 688177 2024 年 4 月 18 日收益和收入增長

Bio-Thera Solutions is not owned by hedge funds. Guangzho Hedy Group Co., Ltd. is currently the largest shareholder, with 39% of shares outstanding. Guangzhou Qiaoxing Investment Partnership Enterprise (Limited Partnership) is the second largest shareholder owning 5.6% of common stock, and Guangzhou Zhongke Yuechuang Incubator Investment Management Co., Ltd. holds about 5.2% of the company stock. Additionally, the company's CEO Shengfeng Li directly holds 1.6% of the total shares outstanding.

Bio-Thera Solutions 不歸對沖基金所有。廣州海迪集團有限公司目前是最大股東,已發行股份的39%。廣州僑興投資合夥企業(有限合夥)是第二大股東,擁有5.6%的普通股,廣州中科悅創孵化器投資管理有限公司持有公司約5.2%的股份。此外,該公司首席執行官李勝峯直接持有已發行股份總額的1.6%。

To make our study more interesting, we found that the top 4 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

爲了使我們的研究更有趣,我們發現前四名股東控制着公司一半以上的股份,這意味着該集團對公司的決策具有相當大的影響力。

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

雖然研究公司的機構所有權數據是有意義的,但研究分析師的情緒以了解風向哪個方向吹來也是有意義的。分析師對該股的報道很少,但報道不多。因此,它還有獲得更多報道的餘地。

Insider Ownership Of Bio-Thera Solutions

Bio-Thera 解決方案的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

不同國家對內部人員的定義可能略有不同,但董事會成員總是計算在內。公司管理層經營業務,但首席執行官將向董事會負責,即使他或她是董事會成員。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部所有權是一件好事。但是,在某些情況下,這使其他股東更難追究董事會對決策的責任。

Our most recent data indicates that insiders own some shares in Bio-Thera Solutions, Ltd.. The insiders have a meaningful stake worth CN¥821m. Most would see this as a real positive. Most would say this shows alignment of interests between shareholders and the board. Still, it might be worth checking if those insiders have been selling.

我們的最新數據顯示,內部人士擁有Bio-Thera Solutions有限公司的部分股份。內部人士持有價值8.21億元人民幣的大量股份。大多數人會認爲這是一個真正的積極因素。大多數人會說,這表明股東和董事會之間的利益一致。儘管如此,可能值得檢查一下這些內部人士是否一直在出售。

General Public Ownership

一般公有制

With a 26% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Bio-Thera Solutions. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Bio-Thera Solutions擁有26%的所有權,主要由個人投資者組成的公衆對Bio-Thera Solutions有一定程度的影響力。這種所有權規模雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。

Private Equity Ownership

私募股權所有權

Private equity firms hold a 5.2% stake in Bio-Thera Solutions. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

私募股權公司持有Bio-Thera Solutions5.2%的股份。這表明他們可以在關鍵政策決策中發揮影響力。一些投資者可能會爲此感到鼓舞,因爲私募股權有時能夠鼓勵制定有助於市場看到公司價值的策略。或者,這些持有人可能會在投資上市後退出投資。

Private Company Ownership

私人公司所有權

It seems that Private Companies own 51%, of the Bio-Thera Solutions stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

看來私營公司擁有Bio-Thera Solutions51%的股份。私營公司可能是關聯方。有時,內部人士通過控股私營公司而對上市公司擁有權益,而不是以個人身份擁有權益。儘管很難得出任何寬泛的結論,但值得注意的是,這是一個需要進一步研究的領域。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Bio-Thera Solutions , and understanding them should be part of your investment process.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,投資風險的幽靈無處不在。我們已經在Bio-Thera Solutions中發現了一個警告信號,了解它們應該是您投資過程的一部分。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

歸根結底,未來是最重要的。您可以訪問這份關於公司分析師預測的免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論